Which Road to Universal Coverage?
Published in The New England journal of medicine
How to Think about "Medicare for All".
Published in The New England journal of medicine
HIV Prevention Efforts and Incidence of HIV in Uganda.
...Published in The New England journal of medicine
In this longitudinal study, the incidence of HIV infection declined significantly with the scale-up of a combination strategy for HIV prevention, which provides empirical evidence that interventions for HIV prevention can have a population-level effect. However, additional efforts are needed to overcome disparities according to sex and to achieve g...
Liraglutide and Renal Outcomes in Type 2 Diabetes.
Published in The New England journal of medicine
Mass Administration of Ivermectin in Areas Where Loa loa Is Endemic.
Published in The New England journal of medicine
A Test-and-Not-Treat Strategy for Onchocerciasis in Loa loa-Endemic Areas.
...Published in The New England journal of medicine
The LoaScope-based test-and-not-treat strategy enabled the reimplementation of community-wide ivermectin distribution in a heretofore "off limits" health district in Cameroon and is a potentially practical approach to larger-scale ivermectin treatment for lymphatic filariasis and onchocerciasis in areas where L. loa infection is endemic. (Funded by...
The Promise, Growth, and Reality of Mobile Health - Another Data-free Zone.
Published in The New England journal of medicine
Levosimendan in Cardiac Surgery.
Published in The New England journal of medicine
Age of Red Cells for Transfusion and Outcomes in Critically Ill Adults.
...Published in The New England journal of medicine
The age of transfused red cells did not affect 90-day mortality among critically ill adults. (Funded by the Australian National Health and Medical Research Council and others; TRANSFUSE Australian and New Zealand Clinical Trials Registry number, ACTRN12612000453886 ; ClinicalTrials.gov number, NCT01638416 .).
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
...Published in The New England journal of medicine
Adjuvant use of combination therapy with dabrafenib plus trametinib resulted in a significantly lower risk of recurrence in patients with stage III melanoma with BRAF V600E or V600K mutations than the adjuvant use of placebo and was not associated with new toxic effects. (Funded by GlaxoSmithKline and Novartis; COMBI-AD ClinicalTrials.gov, NCT01682...
